Trial Profile
A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2 (human estrogen receptor 2)-Overexpressing Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 22 Jan 2013 Planned end date (Nov 2014) added as reported by ClinicalTrials.gov.
- 22 Jan 2013 Planned number of patients changed from 15 to 53 as reported by ClinicalTrials.gov.
- 14 Nov 2007 New trial record.